This Week’s Biopharma News: Big Moves in Bispecifics - Top-Institutions - MDSpire

This Week’s Biopharma News: Big Moves in Bispecifics

Akeso’s PD-1/VEGF bispecific beats PD-1 plus chemo in lung cancer, Amgen wins EC approval for its DLL3-targeted T-cell engager, and Aragen scales Renaissance’s Fast Track anti-GD2 antibody

  • June 9, 2026

  • 5 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Harvard Medical School
    Harvard Medical School

    Boston, MA

    Key Differentiators

    • Hematology

  • #2

    City of Hope
    City of Hope

    Duarte, CA

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    The Ohio State University Comprehensive Cancer Center
    The Ohio State University Comprehensive Cancer Center

    Columbus, OH

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

This Week’s Biopharma News: Big Moves in Bispecifics

  • June 9, 2026

Related Content

Inside VIVEbiotech’s Work with Zelluna on TCR-NK Cell Therapy

VIVEbiotech CEO Jon Alberdi lifts the lid on an eight-year collaboration focused on GMP lentiviral vectors for off-the-shelf solid tumor therapies

  • July 14, 2026

  • 4 min
Dana-Farber Research Supports FDA Approval of New First-Line Therapy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.

  • by

  • June 24, 2026

  • 4 min
Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

  • July 9, 2026

  • 12 min